Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Accumetrics' Plavix prognostic:

This article was originally published in Clinica

Executive Summary

Accumetrics has received US FDA clearance to market its VerifyNow P2Y12 blood test for determining a patient's response to Plavix (clopidogrel) - a drug used by almost 10 million patients in the US to prevent heart attack or stroke. According to the San Diego, California-based firm, some 5-30% of patients do not respond adequately to the drug. The easy-to-perform test, which provides results in less than 15 minutes, works by measuring the inhibiting effect of Plavix on platelets - blood cells primarily responsible for clotting. The test can also be used to assess a patient's clotting function prior to surgery. The company also markets VerifyNow tests for aspirin and GP IIb/IIIa inhibitors.

You may also be interested in...

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts